Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Farmers Insurance
Fish and Richardson
Federal Trade Commission
Express Scripts

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,536,729

« Back to Dashboard

Summary for Patent: 5,536,729

Title: Rapamycin formulations for oral administration
Abstract:The present invention provides novel oral rapamycin formulations which have, per 100 ml of the formulation, from about 0.01 grams to about 5.0 grams of rapamycin, from about 0.05% to about 10% by volume of surfactant, and from about 75% to about 99.95% by volume of a solution of phospholipid or lecithin in which the phospholipid or lecithin therein is 40% to 75% by weight.
Inventor(s): Waranis; Robert P. (Chazy, NY), Leonard; Thomas W. (Willmington, NC)
Assignee: American Home Products Corporation (Madison, NJ)
Application Number:08/301,179
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

No matches for this query

International Patent Family for Patent: 5,536,729

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0648494► SubscribeC00648494/01Switzerland► Subscribe
European Patent Office0648494► SubscribeSPC/GB01/037United Kingdom► Subscribe
European Patent Office0648494► SubscribeSPC020/2001Ireland► Subscribe
European Patent Office0648494► Subscribe01C0037France► Subscribe
European Patent Office0648494► SubscribeC300055Netherlands► Subscribe
European Patent Office0648494► Subscribe24/2001Austria► Subscribe
Denmark0648494► Subscribe
Germany10199046► Subscribe
Canada2133175► Subscribe
Canada2133177► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Boehringer Ingelheim
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: